Description: Capstone Therapeutics Corp. is a biotechnology company. The Company is engaged in developing a pipeline of peptides and other molecules aimed at helping patients with under-served medical conditions. The Company entered into a joint venture, LipimetiX Development, Inc., to develop Apo E mimetic peptide molecule AEM-28 and its analogs for the treatment for Homozygous Familial Hypercholesterolemia, Acute Hypertriglyceridemic Pancreatitis, diabetic dyslipidemia and other hyperlipidemic indications. Apolipoprotein E is a 299 amino acid protein that plays a role in lipoprotein metabolism. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28 and its analogs, including AEM-28-14, a 28 amino acid mimetic of Apo E (with an aminohexanoic acid group and a phospholipid), and both contain a domain that anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan receptors (Syndecan-1) in the liver.
Home Page: www.capstonethx.com
1275 West Washington Street
Tempe,
AZ
85281
United States
Phone:
602-286-5520
Officers
| Name | Title |
|---|---|
| Mr. Michael M. Toporek | CEO, Pres & Chairman |
| Mr. Omar Rabbani | CFO, VP & Treasurer |
| Mr. Wardell M. William | Head of Clinical & Regulatory Review Board |
| Mr. Matthew E. Lipman | VP, Sec. & Director |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 28.0303 |
| Price-to-Book MRQ: | 0.7197 |
| Price-to-Sales TTM: | 0.0867 |
| IPO Date: | 1993-01-28 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |